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ly classified all arterial grafts into 3 types according to
their pharmacological reactivity and embryological ori-
gins1: type I (somatic arteries), type II (splanchnic arter-
ies), and type III (limb arteries). In this classification on
arterial grafts, the radial artery (RA) belongs to the type
III, a type that is more spastic than the type I artery, such
as the internal thoracic artery (ITA).1-4 Considering the
more spastic biological characteristics of this artery,
taken together with the history of the abandonment of
the RA because of its vasospasm problem,5,6 antispastic
therapy for this arterial graft in CABG is particularly
important.7,8 In fact, the revival of the RA largely result-
ed from the use of calcium antagonists.5 However, the
use of calcium antagonists may be contraindicated in
patients with poor left ventricular function and brady-
cardia. The search for the best antispastic method for the
RA is therefore clinically important.
In addition, although many vasodilators such as calci-
um antagonists, ACE-inhibitors, and long-lasting
Autologous arteries have been used as grafts for coro-nary artery bypass grafting (CABG). We have recent-
Objective: The radial artery is a spastic coronary bypass graft. We investi-
gated the effect of the phosphodiesterase III inhibitor milrinone on the
human radial artery. 
Methods: Radial artery segments (n = 76) taken from 15 patients were stud-
ied in an organ chamber. Concentration-relaxation curves for milrinone were
established in the radial artery precontracted with 3 vasoconstrictors
(phenylephrine, K+, and U46619). In radial artery rings incubated with ther-
apeutic plasma concentrations of milrinone (7 and 70 µmol/L) for 10 min-
utes, concentration-contraction curves for the 3 vasoconstrictors were con-
structed. 
Results: Milrinone caused a submaximal relaxation in phenylephrine-
(98.6% ± 1.4%), K+- (89.1 ± 4.5%), or U46619- (74.2 ± 8.0%) precontract-
ed radial arteries at –4.5 log10 M. The EC50 was higher against K+ (–5.85 ±
0.24 log10 M, P = .02) or U46619 (–5.21 ± 0.61 log10 M, P = .03) than
phenylephrine (–6.68 ± 0.11 log10 M). Pretreatment with milrinone
depressed the contraction by phenylephrine from 70.0% ± 7.9% to 23.5% ±
9.3% (P = .003) and by K+ from 138.6% ± 5.8% to 73.0% ± 13.9% (P =
.006) and shifted the EC50 3.8-fold higher (P = .03) for phenylephrine and
2.2-fold higher for K+ (P = .01). Milrinone reduced the U46619 contraction
at low concentration (–8.5 log10 M) but had little effect on the maximal con-
traction. 
Conclusion: Milrinone is a potent vasodilator for the radial artery, with pos-
sibly higher potency in α-adrenoceptor- and depolarizing agent K+–mediat-
ed, but less potency in thromboxane A2–mediated, contraction. Because it
also has a positive inotropic effect, this vasodilator may be particularly indi-
cated for use in patients receiving radial artery grafts in coronary artery
bypass grafting. (J Thorac Cardiovasc Surg 2000;119:1039-45)
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nitrates are available, there is an obvious need for a
vasodilator that also has positive inotropic effects.
Cardiac contraction and vascular smooth muscle relax-
ation are related to the biological activity of second
messengers, including cAMP and cGMP, that are
hydrolyzed by phosphodiesterases (PDEs). PDE
inhibitors are of clinical importance because of their
positive inotropic, as well as vasodilator, effects.9,10 In
coronary bypass surgery, the use of PDE inhibitors may
have a particularly important implication. The positive
inotropic and vasodilator effects of PDE inhibitors are
favorable in the early postoperative period, particularly
for patients with impaired left ventricular function who
have received arterial grafts. In patients undergoing
CABG and receiving arterial grafts, milrinone has been
used clinically for its inotropic and relaxant effects on
the coronary artery as well as on the ITA.11-14
However, the effect of milrinone or other PDE III
inhibitors has been reported to be species- and vessel-
selective.15 As demonstrated by Monrad and associ-
ates,16 milrinone is a direct and selective coronary
vasodilator, compared with its effect on renal or cere-
bral arteries. Despite the fact that milrinone is a potent
vasodilator in animal arteries,10 as well as in human
arteries such as mesenteric arteries17 and the ITA,11-14
the effect of milrinone on the human RA has not been
studied. The present study was therefore designed to
investigate this effect.
Methods
General. Seventy-six human RA segments were collected
from 15 patients (mean age, 64.5 ± 2.0) undergoing CABG
with use of the RA. The preoperative drug therapy was disre-
garded. However, none of the patients received milrinone
therapy. Approval to use discarded RA tissue was given by
the Grantham Hospital Human Ethics Committee. Any redun-
dant or discarded RA segments were collected and placed in
a container with oxygenated, physiological solution (Krebs)
maintained at 4°C, and then transferred to laboratory imme-
diately. The RA was transferred into a glass dish and dissect-
ed out from its surrounding connective tissue. The vessels
were cut into rings 3-mm long and suspended on wires in
organ baths.18,19 The number of rings taken from each patient
varied from 2 to 6. The Krebs solution had the following
composition (in millimoles per liter): Na+ 144, K+ 5.9, Ca2+
2.5, Mg2+ 1.2, Cl– 128.7, HCO3– 25, SO42– 1.2, H2PO4– 1.2,
and glucose 11. The solution was aerated with a gas mixture
of 95% O2-5% CO2 at 37°C.
Organ-bath technique. A technique was used for this
study that allowed vascular rings to normalize to a physio-
logical pressure in the organ bath. The vascular rings were set
at a pressure comparable to that in the in vivo situation. The
details of the technique were published before.18,19 Briefly,
the rings were stretched in progressive steps to determine the
length-tension curve for each ring. A computer iterative fit-
ting program (VESTAND 2.1; Yang-Hui He, Princeton, NJ)
was used to determine the exponential line, the pressure, and
the internal diameter. When the transmural pressure on the
rings reached 100 mm Hg, as determined from their own
length-tension curves, the stretch procedure was stopped and
the rings were released to 90% of their internal circumference
at 100 mm Hg. This degree of passive tension was then main-
tained throughout the experiment.
The endothelium was intentionally preserved by cautiously
dissecting and mounting the rings, since endothelium plays a
modulatory role in the contractility of arterial grafts.20 We pre-
viously found that this technique allowed for a functionally
intact endothelium, as determined by the functional relaxation
response to substance P or calcium ionophore in the RA.2
Protocol. After the normalization procedure, the RA rings
were equilibrated for at least 45 minutes. Two experimental
protocols, relaxation and depression of contraction by pre-
treatment with milrinone, described below, were designed (in
this study, multiple RA rings taken from each patient were
allocated to different experimental groups). 
Relaxation. Milrinone-induced relaxation was studied in RA rings
contracted with potassium chloride (K+, 25 mmol/L, n = 7), U46619
(10 nmol/L, n = 7), and phenylephrine (3 µmol/L, n = 7). The concen-
trations of these vasoconstrictor substances were submaximal,as deter-
mined from the logistic-curve fitting equation.18,19 These concentra-
tions are equal to EC50 to EC80 for the U46619-, K+-, and
phenylephrine-induced contraction in the human RA from the present
study. Cumulative concentration-relaxation curves to milrinone were
then established. Only 1 concentration-relaxation curve was obtained
from each RA ring. A mean concentration-relaxation curve was con-
structed as shown in a group of rings.
Depression of contraction by pretreatment with milrinone.
After equilibration, 100 mmol/L K+ was added to the organ bath
and the contraction force was recorded. The ring was frequent-
ly washed to restore the baseline. To determine whether pre-
treatment with milrinone would alter the contraction response
to various vasoconstrictors (phenylephrine, K+, and U46619),
we constructed cumulative concentration-contraction curves
from RA ring segments. These rings were equilibrated for 10
minutes with 7 or 70 µmol/L milrinone. These concentrations
were chosen since they are similar to optimal plasma concen-
tration reached clinically.21 The time for the pretreatment was
chosen from the average time to reach a plateau for each dose
of milrinone in the relaxation experiments in the present study.
Contraction was expressed as a percentage of the contraction
force induced by 100 mmol/L K+.
Phenylephrine. Three or four rings were taken from each
of 6 patients. One or two of these rings were used as a con-
trol, and the other two were equilibrated for 10 minutes with
one of the two concentrations (7 or 70 µmol/L) of milrinone.
A cumulative concentration-contraction curve was then con-
structed for phenylephrine.
K+. Three rings were taken from each of 6 patients. One of
these rings was used as a control, and the other two were
equilibrated for 10 minutes with one of the two concentra-
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tions (7 or 70 µmol/L) of milrinone. A cumulative concentra-
tion-contraction curve was then constructed for K+. 
U46619. Three rings were taken from each of 6 patients.
One of these rings was used as a control, and the other two
were equilibrated for 10 minutes with one of the two concen-
trations (7 or 70 µmol/L) of milrinone. A cumulative concen-
tration-contraction curve was then constructed for U46619.
Data analysis. The data are presented as mean ± standard
error of the mean (SE). The effective concentration of the
constrictor (or dilator) agent that caused 50% of maximal
contraction (or relaxation) was defined as EC50 (-log10 M).
The EC50 was determined from each concentration-contrac-
tion (or relaxation) curve by a logistic, curve-fitting equation:
E = MAp / (Ap + Kp )
where E is response, M is maximal contraction (or relax-
ation), A is concentration, K is EC50 concentration, and p is
the slope parameter.18,19 A computerized program was used
for the curve-fitting. 
From this fitted equation, the mean EC50 value was calcu-
lated in each group. Unpaired t test or analysis of variance
was used to test statistical significance among different con-
strictors and dilators regarding the maximal response or
EC50. The Scheffé test was used as post hoc test between 2
groups when ANOVA was used to compare among 3 groups.
P < .05 was considered significant.
Materials. Drugs used in this study and their sources were
as follows: phenylephrine (Sigma, St Louis, Mo); U46619
(Cayman Chemical, Ann Arbor, Mich); stock solution of
U46619 was held frozen until required; milrinone was gener-
ously provided by Sterling-Winthrop Pharmaceutical
Research Division.
Results
Resting vessel variables. The mean internal diame-
ter of the 76 rings at an equivalent transmural pressure
of 100 mm Hg (D100) was 2.5 ± 0.2 mm as determined
from the normalization procedure.18,19 When the RA
rings were set at a resting diameter of 0.9 × D100, the
equivalent transmural pressure was 71.1 ± 1.9 mm Hg,
and the resting force was 2.1 ± 0.4 g.
Relaxation by milrinone in the RA precontracted
by phenylephrine, K+, or U46619. Milrinone caused a
submaximal relaxation in U46619- (74.2% ± 8.0%),
phenylephrine- (98.6% ± 1.4%), or K+- (89.1% ± 4.5%)
precontracted RA (Fig 1) at the concentration of –4.5
log10 M. The EC50 was significantly higher against K+-
(–5.85 ± 0.24 log10 M, 95% confidence interval [CI]:
0.17 ~ 1.50 log10 M, P = .02), or U46619 (–5.21 ± 0.61
log10 M, 95% CI: 0.12~2.83 log10 M, P = .03) than
phenylephrine (–6.68 ± 0.11 log10 M) (unpaired t test). 
Depression of contraction by pretreatment with
milrinone.  Pretreatment with milrinone significantly
inhibited phenylephrine-induced contraction (P = .016,
Fig 2). In comparison to 70.0% ± 7.9% in the control,
the maximal contraction was reduced to 63.4% ± 9.2%
and 23.5% ± 9.29% (95% CI: 19.9~73.1%, P = .03,
Scheffé test) with the treatment of milrinone at the con-
centration of 7 or 70 µmol/L. The treatment of milri-
none also changed the EC50. Pretreatment with 70
µmol/L milrinone shifted the EC50 3.8-fold (95% CI:
–11.5 ~ –1.3) higher (Table I, P = .02, 95% CI: –1.06 ~
–0.12 log10 M). 
Pretreatment with milrinone also significantly inhib-
ited K+-induced contraction (P = .016, Fig 3). In com-
parison to 138.6% ± 5.76% in the control, the maximal
contraction was reduced to 117.3% ± 4.0% and 73.0%
± 13.9% (95% CI: 32.1 ~ 99.1%, P = .006, Scheffé test)
with the treatment of milrinone at the concentration of
7 or 70 µmol/L. The treatment of milrinone also
changed the EC50. Pretreatment with 70 µmol/L of mil-
rinone shifted the EC50 2.2-fold higher for K+ (Table I,
95% CI: –39.5 ~ 12.8 mmol/L, P = .01).
In contrast, in U46619-induced contraction, the pre-
treatment with milrinone did not significantly reduce
the maximal contraction (Fig 4 and Table I). However,
at a lower concentration (–8.5 log10 M), treatment of
milrinone significantly reduced the U46619-induced
contraction (P = .02, Fig 4).
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Fig 1. Mean concentration (–log10 M)-response (% relax-
ation) curves for milrinone in the human radial artery pre-
contracted by potassium chloride (closed circles, K+, 25
mmol/L, n = 7), phenylephrine (open circles, 3 µmol/L, n =
7), and U46619 (triangles, 10 nmol/L, n = 7). The rings were
taken from 6 patients. Vertical error bars are 1 SEM of mean
values. 
Discussion
In this study of the human RA, the alternative arteri-
al graft for coronary artery bypass surgery, we have
found that (1) milrinone at clinically relevant concen-
trations is a potent vasodilator that inhibits the contrac-
tion mediated by various vasoconstrictors and that (2)
milrinone may have slight selectivity with higher
potency to α-adrenoceptor- and depolarizing agent
K+–mediated contraction than the contraction mediated
by thromboxane A2 (TXA2). 
Intracellular cAMP and cGMP play a role in modula-
tion of vascular smooth muscle tone.22 Concentrations
of cAMP and cGMP are controlled through synthesis by
cyclases and through hydrolysis by PDEs. PDEs are
classified into at least 5 types.23 PDE III inhibitors, such
as amrinone or milrinone, are known to inhibit cGMP-
inhibitable low Km cAMP PDE.10 The pharmacologic
activities of PDE III inhibitors are to increase cardiac
contractility, reduce pulmonary and systemic resistance,
and inhibit platelet aggregation.15,24 The cardiac and
vascular smooth muscle actions are favorable in the
postoperative management of patients who undergo
heart surgery, particularly in patients who have ventric-
ular dysfunction and received arterial grafts for coro-
nary artery bypass surgery.
In the present study, the α1-adrenoceptor agonist
phenylephrine, K+, and TXA2 mimetic U46619, were
used to contract the RA. The human RA has been
demonstrated to be an active artery that responds to
many vasoconstrictors.2,3,7,25 Therefore, it was neces-
sary to test the effect of milrinone on the contraction
mediated by various vasoconstrictors. In particular,
exogenous and endogenous sympathomimetic amines
have been demonstrated to be spasmogens for arteries26
and α1-adrenoceptors have been demonstrated to be
predominant in the human RA.25 In addition, during
cardiopulmonary bypass TXA2 has been shown to have
increased plasma concentrations.27 For these reasons,
phenylephrine, an α1-adrenoceptor agonist, and
U46619, a TXA2 mimetic, were used to contract the
RA. The contraction mediated by the depolarizing
agent K+ was also studied since this is the primary
mechanism for vasoconstriction.
This study shows that milrinone is a potent vasodila-
tor of the RA. It almost fully relaxed the contraction
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Fig 2. Mean concentration (–log10 M)-contraction (percent-
age of 100 mmol/L K+-induced contraction) curves for
phenylephrine. Three rings obtained from each patient were
allocated to each treatment. One ring was the control (closed
circles) without pretreatment of milrinone. For the other 2
rings, milrinone 7 (open circles) or 70 (triangles) µmol/L
was added into the organ bath 10 minutes before the start of
the phenylephrine curve. Symbols represent data averaged
from a group of rings (taken from 6 patients). Vertical error
bars are 1 SEM of mean values; double asterisks, P < .01,
ANOVA among the 3 groups and Scheffé test compared with
the control at the maximal contraction.
Fig 3. Mean concentration (-log10 M)-contraction (percent-
age of 100 mmol/L K+-induced contraction) curves for K+.
Three rings obtained from each patient were allocated to each
treatment. One ring was the control (closed circles, n = 6)
without pretreatment of milrinone. For the other 2 rings, mil-
rinone 7 (open circles, n = 6) or 70 (triangles, n = 6) µmol/L
was added into the organ bath 10 minutes before the start of
the K+ curve. Vertical error bars are 1 SEM of mean values;
triple asterisks, P < .001, Scheffé test compared with the con-
trol at the maximal contraction.
induced by all of the three vasoconstrictors at a con-
centration of –4.5 log10 M (Fig 1). The EC50s for
phenylephrine-, K+-, and U46619-induced contraction
are between –6.68 and –5.21 log10 M (0.2 and 6.2
µmol/L) (see “Results”). The therapeutic plasma con-
centration for milrinone was measured by Likoff and
associates27 at 1479 ± 849 ng/mL after intravenous
bolus infusion of 50 µg/kg, and this concentration
translates to about 7 µmol/L. In our experiments, this
concentration relaxed nearly 100% of phenylephrine-,
75% of K+-, and 60% of U46619-precontracted RAs.
Further, in the present study, we also studied the effect
of milrinone at the 10-fold higher concentration (70
µmol/L), and the results showed that this concentration
of milrinone further relaxed the contraction mediated
by all 3 vasoconstrictors. Taken together, the therapeu-
tic plasma concentration and the experimental results
from the present study show that milrinone is a clini-
cally potent vasodilator for the RA. Even in U46619-
contracted RA, in which milrinone was least potent, as
demonstrated by a higher EC50 (5.21 log10 M [6.2
µmol/L]) compared with the other vasoconstrictors,
this EC50 value is still within the therapeutic plasma
concentration as described above.
On the other hand, pretreatment of milrinone may
have a selectivity on inhibition of various vasoconstric-
tor-induced contractions if used before vasoconstrictor.
In phenylephrine- and K+-mediated contractions, pre-
treatment with milrinone significantly reduced the
maximal contraction, and the EC50 was significantly
higher with milrinone treatment in contractions medi-
ated by both vasoconstrictors. In contrast, in U46619-
induced contraction, although at lower concentrations
milrinone significantly reduced the contractions (Fig
4), the maximal contractions were not significantly
altered by the pretreatment of milrinone.
We have previously reported the vasorelaxant effect
of milrinone in the human ITA.11 Milrinone has a sim-
ilar effect in the RA in phenylephrine- and U46619-
mediated contraction. However, the inhibitory effect of
milrinone in the K+-mediated contraction is more sig-
nificant in the RA. As demonstrated in the present
report, milrinone significantly depressed maximal con-
traction induced by K+ at both concentrations (7 and 70
µmol/L). This difference may suggest that milrinone
may have even better vasorelaxant effect in the RA than
the ITA; therefore, use of milrinone may have an espe-
cially desirable benefit in patients with an RA graft.
In previous studies, we have found that some
vasodilators, such as nitroglycerin, are markedly able
to reverse the existing vascular contraction but are less
effective if applied before the contraction.11,18 As
described by Maurice and colleagues,28 there may be
critical differences in the state of the vascular smooth
muscle before and after induction of contraction that
affect the responses to vasodilator substances.
Increases in intracellular Ca2+ concentration and the
phosphorylation of myosin light chain are important in
the contraction of vascular smooth muscle29; therefore,
compounds that block these processes will inhibit con-
traction. However, relaxation of smooth muscle that
involves reversal of a latch state is less dependent on
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Table I. Inhibition of milrinone on the contraction (mean ± SE) induced by various vasoconstrictors in the human
radial artery
Maximal Contraction to
contraction (g) K+ (100 mmol/L) (g) % P Value Ec50 (−log10 M) P Value
K+
Control 12.6 ± 1.4 9.2 ± 1.0 138.6 ± 5.8 .0004 21.5 ± 2.6 .018
Milrinone (7 µmol/L) 9.2 ± 0.7 7.8 ± 0.4 117.3 ± 4.0 35.0 ± 7.2
Milrinone (70 µm) 6.3 ± 1.3 8.6 ± 0.9 73.0 ± 13.9 47.6 ± 5.7*
Phenylephrine
Control 4.5 ± 0.8 6.7 ± 1.2 70.0 ± 7.9 .004 −5.86 ± 0.17 .03
Milrinone (7 µmol/L) 3.9 ± 0.5 6.8 ± 1.4 63.4 ± 9.2 −5.50 ± 0.13
Milrinone (70 µm) 0.9 ± 0.3 5.7 ± 1.3 23.5 ± 9.3* −5.28 ± 0.08†
U46619
Control 12.4 ± 2.4 9.1 ± 1.5 143.6 ± 20.6 .9 −7.93 ± 0.15 .47
Milrinone (7 µmol/L) 11.6 ± 2.6 8.2 ± 1.7 148.1 ± 13.5 −7.27 ± 0.62
Milrinone (70 µm) 10.2 ± 2.0 8.9 ± 1.6 142.1 ± 45.2 −7.67 ± 0.09
%, Percentage of the maximum contraction (g) divided by the contraction induced by 100 mmol/L K+; EC50, the drug concentration causing 50% of the
maximal effect, derived from a logistic curve fitting program (see “Methods”); EC50 for K+ is in millimoles per liter.
P values are ANOVA among the 3 groups.
*P < .05, Scheffé test as the post hoc test, compared with the control.
†P < .01, Scheffé test as the post hoc test, compared with the control.
the inhibition of Ca2+ mobilization or on dephosphory-
lation of myosin.30 In the present study, we have
demonstrated that the effect of milrinone also depends
on the state of the contraction in the human RA. In the
present study, this is more obvious in the contraction
mediated by U46619 and K+. In the RA precontracted
with either U46619 or K+, –4.5 log10 M (30 µmol/L)
milrinone relaxed the vessels to more than 60% (Fig 1).
In contrast, even a higher concentration (–4.15 log10 M,
70 µmol/L), milrinone only inhibited the contraction of
the arteries to 54% (Fig 3) of the K+-induced contrac-
tion and had no effect on the maximal contraction
induced by U46619. These data further demonstrate
that the differences between relaxant effect and inhibi-
tion of contraction demonstrated in the present study
are constrictor-dependent.
In conclusion, the results of our study suggest that mil-
rinone is a potent vasodilator for the human RA. It may
have selectivity with a greater effect to α-adrenoceptor-
and depolarizing agent K+-mediated contraction than the
contraction mediated by TXA2, and the inhibitory effect
in depolarizing agent–mediated contraction may be
superior in the RA to that in the ITA. Because it also has
a positive inotropic effect, this vasodilator may have par-
ticular indications to be used in patients receiving RA
grafts during coronary bypass operations.
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